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1. ABSTRACT  
 
Bipolar disorder (BD) is a severe chronic multifactorial disease that requires maintenance therapy with mood 
stabilizers (MS). Even with medications, the rate of response among patients with BD is low and the risk of relapse is high. 
Therefore, in this context of the urgent need for reliable and reproducible predictors of individual responses to MS, 
pharmacogenetics research is expected to provide helpful progress. Most pharmacogenetic studies of MS have focused on the 
response to lithium with several good putative candidate genes but informative results are sparse. There have been few studies on 
valproate, lamotrigine or atypical antipsychotics. Overall, the results of pharmacogenomics studies have not provided sufficient 
data to change daily practices in BD significantly and further investigation is warranted to identify highly relevant genetic 
predictors of response their roles. Although progress still remains to be made, the clinical assessment of a subject including the 
identification of specific individual phenotypic and pharmacogenetic characteristics is likely to become a powerful instrument for 
the development of personalized therapies. 
 
2. INTRODUCTION 
 
Bipolar disorder (BD) is a chronic multifactorial psychiatric disorder that is characterized by recurrent alternating 
episodes of mania/hypomania and depression interspaced with euthymic periods variably affected by residual symptoms and 
dysfunction (1). BD causes impairment in functioning and health-related quality of life, and BD patients require maintenance 
therapy (2). The lifetime prevalence of BD is about 1% for the traditional BD I subtype and up to 6.5% if all BD spectrum 
subtypes are included; thus, it is evidence that BD is a major public health problem (3,4). Indeed, BD is seventh most major cause 
of disability-adjusted life-years according to the World Health Organization (WHO) (5). 
 
The etiological determinants of BD remain poorly understood; similarly, the mechanisms of action of psychotropic 
drugs have not been described in detail, and indeed the exact targets are still to be definitively identified. Current guidelines 
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advocate the use one of a group of variably similar treatment algorithms for all patients, such that the clinical, pathophysiological, 
and lifetime heterogeneity of BD is not taken into accounts, because of the lack of evidence (2). Thus, personalized therapeutic 
strategies with targeted interventions —taking into account both individual characteristics and the characteristics of the clinical 
expression of the disorder in a given individual— are clearly required to improve prognosis. Pharmacogenomics can be exploited 
to identify key biomarkers and therefore drive innovation in this field of personalized medicine.  
 
Numerous studies have attempted to identify genetic markers that could be used to predict drug efficacy and safety in 
several fields of medicine. Pharmacogenetics is ―the study of variability in drug response due to heredity‖, and may thus be 
contribute to the development of ‗personalized‘ treatment strategies in medicine, and including BD. However to date, there is 
only one US FDA-approved commercial pharmacogenetic test available (Roche Diagnostic, AmpliChip CYP450) which allows 
genotyping for the two cytochrome P450 genes (CYP2D6 and CYP2C19). Using this chip, patients can be genotyped to help 
predict the metabolizer status of patients, which may influence choice and dose of antipsychotic or antidepressant medication (6). 
No clear genetic biomarker for use in routine clinical care in BD has been described. 
  
This is particularly unfortunate because BD patients show a low rate of response, a high risk of relapse and several side 
effects to MS that are unfortunately not predictable. Indeed, survival analysis of BD patients indicates a 5-year risk of relapse into 
mania or depression of 73% despite continual and adequate MS medication (7). Even for those who do not relapse, considerable 
affective morbidity is observed (7). The large EMBLEM prospective study with BD I patients shows that 64% achieved 
remission and 34% achieved functional recovery at 2 years (8). A naturalistic observation study of the response to MS described 
very low rates of full response to individual MS: lithium 30%, carbamazepine 0%, valproate 13%, lamotrigine 11%, and 
olanzapine 25% (9). The predictors were few and uncertain: lithium responders were more likely to be bipolar II with earlier 
onset of illness, and responders to valproate presented higher rates of psychosis (9). Various evidence indicates that the response 
to long-term lithium treatment is a familial trait and clusters in families (10). Also, the mode of inheritance of BD responsive to 
lithium appears to conform to a recessive model with sex-specific penetrance of transmission (11). Evidence for such heritability 
is consistent with the relevant genes exerting a high-magnitude effect on the response to long-term lithium treatment. Thus, the 
response to long-term prophylactic treatment with mood stabilizers (MS) has been suggested to be a clinical trait that could be 
exploited to identify homogeneous subgroups of BD and to map genes relevant to both treatment response and BD itself (12–15). 
Therefore, informative and helpful results are expected from pharmacogenomics research in this context of the urgent need to 
find reliable and reproducible predictors of individual responses to MS and MS safety (14,16–18).  
 
We review the current state of, and perspectives for, pharmacogenetic research on MS treatments in BD. First, we 
consider issues pertaining to the diagnosis of BD patients, sample selection and definitions of treatment response phenotypes 
used in various pharmacogenetic studies. Then, we review existing evidence for genetic predictors of the response of BD patients 
to MS treatment. Finally, we discuss the possible challenges and future directions for pharmacogenetics in BD. 
 
3. METHODS 
 
We conducted in March 2013 an extensive review on the pharmacogenomics studies exploring MS treatment in BD. 
The publications were obtained from the PubMed electronic database. The literature search was performed using the Mesh 
heading: ―Bipolar Disorder‖ AND ("genetics" OR "gene" OR ―pharmacogenomics‖ OR ―pharmacogenetics‖) AND ("mood 
stabilizer" OR "lithium" OR "valproate" OR "valproic acid" OR "lamotrigine‖ OR "carbamazepine‖ OR "oxcarbazepine‖ OR 
"topiramate‖ OR "gabapentin‖ OR "antipsychotic‖). We also used the related articles function of the PubMed database, the 
reference list of retained studies and searched Google Scholar to identify additional articles. We included only published data 
written in English. 
 
4. PHENOTYPIC FEATURES AND DEFINITIONS 
 
A research in pharmacogenetics is confronted by a methodological question: should the response to MS treatment in all 
BD subjects be studied, or should phenotypically defined subgroups of subjects with BD be studied? 
 
The genetic and phenotypic heterogeneity of BD clearly cloud the identification of its biological determinants (19). 
The use of valid and consensual definitions for all steps of studies is essential for reliable and comparable results to be obtained. 
Rigorous definitions of the probands and clear criteria for the definition of treatment are needed to detect causative determinants 
of differences in response to medication.  
 
4.1. Which phenotype should be assessed for subjects with BD? 
Investigations of drug responders (20) and the comparison of patients responsive to different drugs (21) have led to 
promising results. Responsive patients that differ with respect to course of the disease, comorbidity and family history, may 
represent distinct subtypes of BD. There is now evidence to suggest that lithium-responsive BD is a core bipolar phenotype (20): 
responders to lithium show a family history of BD and a familial response to lithium consistent with genetic factors having a 
prominent role (20). Also, family histories and some clinical characteristics differ between responders to lithium and responders 
to other MS (20).  
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BD is a broad-large spectrum with wide range of symptoms. Defining intermediate phenotypes, or homogeneous 
subgroups within the BD population may be useful. Indeed, the early genetic research with the whole BD spectrum, or even with 
the traditional BD I subgroup, failed to obtain significant and relevant results (19). Consequently, recent studies focus on more 
homogeneous subgroups, and there has been substantial effort directed towards phenotypic refinement. The purpose of 
phenotypic refinement is to select subgroups that differ from the whole BD population as concerns clinical presentation, course 
of the disease, family history, comorbidities and/or possibly long-term response to treatment (22). Alda proposed a classification 
based on three main subtypes of BD: (1) classical, (2) psychosis spectrum and (3) 'characterological' which includes cases with 
distinct clinical characteristics and specific patterns of drug treatment response that might lead to more targeted treatment (23).  
 
Such phenotype selection of BD populations aims to increase the probability of identifying genes of interest. They 
highlight the importance of careful diagnostic assessment of BD cases, with attention to specific clinical features, family history, 
comorbidities and clinical course as these factors may be closely linked to the treatment response phenotype. 
 
4.2. How should treatment response phenotypes be assessed? 
Assessment of treatment response phenotypes is central to identifying the role of genetic factors in determining a 
subject‘s response to a drug or the onset of adverse drug reactions (ADR). The definitions of treatment response used in the 
literature are often not clear and divergent between pharmacogenetic studies. Defining treatment response phenotypes is expected 
to be highly complex, largely because the clinical quantification of the response to treatment is complex. 
 
The simplest phenotype is dichotomous (responders/non-responders) and has been used in most pharmacogenetic 
studies of MS (14). Nevertheless, a binary trait of this type does not allow correct measurement of the response to a drug, which 
is, constitutively, a quantitative trait. Indeed, such binary measurement does not reflect the clinical reality because most patients 
show partial responses and very few of presented a full response to MS (9). If a categorical approach is used, partial responses to 
a drug can be usefully assessed in addition to the classical traits of responders/non-responders. Applying a dimensional approach, 
the response to MS is studied as a quantitative trait, and this may facilitate the identification of genetic variants and their 
expression associated with a wide range of intermediate phenotypes. The dimensional approach allows the degree of variation in 
the treatment response phenotype to be studied, and this contrasts with the dichotomous approach that only the two extreme 
points of the dimensional gradient into account. Moreover, combining assessment of the response to treatment as measured from 
the improvement of BD symptoms, with assessment of treatment side effects, as with the Clinical Global Impressions Scale 
(CGI), might be useful to separate out the two effects (24). The method of ―extreme discordant phenotype‖ (EDP) may increase 
the statistical power and consequently the probability of detecting gene variants associated with drug efficacy or toxicity (25). 
Alternatively, individual trait values, for example treatment response, can be used as indices for phenotype selection, and 
selective genotyping has been proven to be effective for mapping quantitative trait loci (QTL) (26).  
 
The definition of treatment response is complex, especially in BD: several factors have to be considered, including the 
long-term response to MS, the severity and the duration of episodes before and after the introduction of the MS, the presence of 
possible confounders, for example multiple pharmacotherapy, and the degree of compliance. Thus, stringent definitions are tricky 
to establish, and several tools have been proposed. The average Affective Morbidity Index and the Illness Severity Index are both 
analytical tools (27) (28). They each provide a quantitative evaluation of the improvement under MS and take into account both 
severity and duration of episodes before and after the introduction of MS treatment. However, they suffer limitations because 
they do not take the presence of confounders into account, such as compliance or poly-pharmacotherapy. Grof et al. recently 
compared response to long-term lithium treatment in bipolar relatives of BD lithium responders and BD controls, and proposed a 
more complete rating scale referred to as the ―Alda scale‖ (10). It is a quantitative scale for measuring the degree of improvement 
under MS taking the presence of confounders into account. As well as allowing improvement due to MS only to be observed, it 
also permits both an intermediate phenotype approach (partial response to MS) and an EDP approach (10). This approach 
involves rating the degree of response on a 10-point scale (―A‖ criteria) and the number of episodes off the treatment, the 
frequency of episodes off the treatment, the duration of treatment, the compliance during period (s) of stability, and the use of 
additional medications during the periods of stability (―B‖ criteria); a total score from 0 to 10 is then obtained by subtracting B 
from A criteria (10).  
 
However, irrespective of the definition used, we observed that the rate of response to various MS treatments in 
monotherapy is always close to 50% (and about 30% for placebo), with an incremental benefit of about 20% when adding a 
second MS agent (29). Thus, treatment refractoriness in BD remains a substantial medical challenge. We believe therefore that it 
is very important to identify markers that are predictive of the response to MS treatments; this may involve the identification of 
genetic variant patterns that can be used to help choose between different molecules available as treatment in routine practice. 
 
5. PHARMACOGENOMICS OF MOOD STABILIZERS 
 
5.1. Lithium 
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Lithium salts are the best studied MS and remain a cornerstone of treatment in BD. Pharmacogenetic studies have for 
the most part focused on the response to lithium prophylaxis as a way to define a more homogeneous population (Table 1). 
 
5.1.1. Linkage studies on the response to lithium  
Linkage studies on the response to lithium were the first to generate relevant and informative results. Analysis of the 
Faroese population with eight lithium-responsive BD probands provided evidence of increased haplotype sharing on the distal 
part of chromosome 18q23, confirming the preliminary findings for this region by Freimer et al. (30). A linkage study focused on 
this region of chromosome 18: in the sample of lithium-responsive BD probands including only unilineal families, two 
chromosomal regions with modestly positive LOD scores were found at D18S53 and at D18S61 for maternal and paternal 
pedigrees, respectively (31). Further linkage studies using a temperament-based measure (cyclothymic temperament) as a 
quantitative intermediate phenotype found the highest linkage on chromosome 18p11 and weaker linkage for chromosomes 3 and 
7 (32). Consequently, chromosome 18 is a potential region of interest and quantitative measures may lead to the detection of loci 
for BD and maybe for the response to lithium. Work with a very large pedigree derived from a homogeneous population in 
Quebec from Saguenay-Lac-St-Jean area found the chromosome 12q23-q24 region to be linked with the response to lithium in a 
BD population (33). Linkage to chromosome 12q24 was confirmed later in a larger study in the same population, and other 
regions of lower interest were found on chromosomes 2, 5, 7, 9, 10, 17 and 20 (34). Evidence for linkage was found in 31 BD 
families identified as excellent lithium responders with loci on chromosomes 15q14 and 7q11.2 (35); considering response 
phenotype, this study also suggests that chromosome 7q11.2 may be more involved in the response to lithium than chromosome 
15q14, which was implicated in the etiology of BD (35). These observations highlight how it is important to pay attention to the 
interpretation of studies of this type. Indeed, comparing responders to non-responders allows treatment response genes to be 
identified, whereas studying BD responders alone only allows conclusions about genes associated with the disease. A very 
relevant recent linkage study considered 36 families recruited through responsive probands to long-term lithium treatment; it 
involved an initial linkage study followed by fine mapping and gene expression analysis. Exploiting these two complementary 
strategies, the authors found evidence of linkage to lithium-responsive BD in 3p25, 3p14 and 14q11 regions; they also found 
significantly deregulated synaptic and mitochondrial genes in these regions (36).  
 
These linkage studies on the response to lithium generated enthusiastic results and should also be performed in the 
future on the ―non-response‖ phenotype. Moreover, some methodological issues, such as spontaneous remission of the illness, 
will have to be addressed. 
 
5.1.2. The candidate gene approach 
5.1.2.1. The inositol pathway 
Selecting candidate genes for pharmacogenetic investigation is difficult because the exact mechanism of action of 
lithium remains unclear (37). Lithium inhibits the activity of several enzymes including those involved in the 
phosphatidylinositol cycle and in phospholipase C signal transduction that may be responsible for mood stabilization. Williams 
RS et al. reported that the effects of MS (including valproate and carbamazepine as well as lithium) are mediated through action 
on inositol depletion (38). They demonstrate that all three drugs inhibit the collapse of sensory neuron growth cones and increase 
growth cone area, and that this action is reversed by inositol (38). Consequently, numerous candidate gene studies on the 
response to lithium prophylaxis have addressed inositol-related genes.  
 
The hypothesis that inositol polyphosphate 1-phosphatase (INPP1) in the phospholipase C signaling pathway is a 
putative target of lithium has been investigated: several pharmacogenetic studies have tested for associations between 
polymorphisms in the INPP1 gene and the response to lithium of BD patients. An association between the C973A variant of the 
INPP1 gene and good efficacy of lithium in BD has been reported (39), but not subsequently confirmed by Michelon et al. (40).  
 
Candidate genes studies have drawn attention to the myo-inositol monophosphatase 2 (IMPA2) that encodes an 
enzyme of the phosphatidylinositol signaling system and is inhibited by lithium (41). One study compared good responders to 
lithium treatment with the poor responders among 237 parent-offspring trios, 174 cases and 170 controls: this study reported a 
trend for significant associations in predicting the response to lithium treatment for two polymorphisms (41). The two 
polymorphisms of IMPA2 on chromosome 18p11.2 were confirmed in a supplementary study (42). Two studies found no 
association between the polymorphisms of myo-inositol monophosphatase 1 (IMPA1) on chromosome 8q21.13-21.3 with 
variation in the response to lithium treatment in cases of BD (42,43). Generally, preliminary studies implicate several enzymes 
related to inositol phosphate metabolism and therefore the genes of this pathway may be suitable targets for studies of the action 
of lithium.  
 
Diacylglycerol kinase eta (DGKH) is a key protein in the lithium-sensitive phosphatidyl inositol pathway responsible 
for the recycling and degradation of diacylglycerol (DAG). A recent genome-wide association study implicates the diacylglycerol 
kinase eta gene (DGKH), and found the strongest association signal at a marker within the first intron of DGKH (44). However, 
study of a sample of 199 Sardinian BD patients characterized for the response to lithium therapy did not replicate the association 
with DGKH polymorphisms (45), and an additional study in 91 subjects characterized for lithium response did not find an 
association but the sample was too small to detect anything other than large, strong effects (46). 
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Several studies have tested the phospholipase C-gamma 1 (PLCG1) gene that codes for a gamma-1 isozyme of 
phospholipase (PLC), an enzyme of the inositol pathway second messenger system. One study reported a positive association for 
one PLCG1 polymorphism in 136 excellent lithium responders compared to 163 controls (47). The same authors screened the 
PLCG1 gene for functional polymorphisms and identified three polymorphic sites in three different exons (exons 9, 26, 31); 
however, none of the markers was found to be associated with BD in a sample of 133 excellent responders to lithium and 99 
healthy controls (48). Because of the absence of a comparison non-responder group, these two studies only show that the PLCG1 
gene is associated with BD. A recent study tried to confirm the findings that bipolar patients with an excellent response to lithium 
treatment have a higher frequency of a specific dinucleotide repeat allele in the PLCG1 genomic region; however, this was not 
replicated in a sample of Norwegian lithium-treated bipolar patients sub-classified as lithium responders, non-responders, or 
partial-responders/unclassified (49).  Only a PLCG1-8 repeat was more frequent among lithium responders than controls when 
analysing according to presence or absence of different dinucleotide alleles (49). Although further studies are needed to explain 
these contradictory results, work in the inositol pathway shows promise and generates helpful findings. 
 
5.1.2.2. The circadian signaling system 
There is interest in variants of genes associated with the molecular clock, as some of these genes encode enzymes that 
are inhibited by lithium, for example glycogen synthase kinase 3 alpha and beta (GSK3α and GSK3β). Lithium acts on these 
enzymes either by direct inhibition or indirectly by regulating other mechanisms like the formation of a signaling complex 
comprised of beta-arrestin 2 (βArr2) and Akt. (50). Benedetti et al. studied the association of GSK3β (-50 T/C) polymorphism 
with the therapeutic response to lithium among 88 bipolar type I patients: the recurrence index for homozygotes for the wild 
variant (C/C) did not change under treatment, whereas carriers of the mutant allele showed improvement. This thus suggests that 
the long-term response to lithium in bipolar illness is influenced by the GSK3β -50 T/C polymorphism (51). However, 
contradictory results have been reported: one study concluded that this polymorphism is not related to the response to 
prophylactic lithium (52) and another found no association (40). GSK3β also phosphorylates and stabilizes the orphan nuclear 
receptor REV-ERBα, one of the principal components of the circadian rhythm system that is involved in the cyclic regulation of 
Brain and Muscle Arnt-like protein-1 (BMAL1). Lithium induces degradation of REV-ERBα and BMAL1 gene expression, 
implicating REV-ERBα as a target of lithium in its mechanism of action (53). The association of the gene encoding for REV-
ERBα (NR1D1) and the response to lithium prophylaxis in BD patients has been investigated in a sample of 199 Sardinian BD 
patients characterized for the response to lithium therapy; the interaction analysis did not show any significant effect of any 
NR1D1 polymorphisms (45). However, more recently, Campos-de-Sousa et al. observed a significant association between the 
variant rs2314339 in NR1D1 and the response to lithium (54). Further evidence of a role for REV-ERBα in the therapeutic 
mechanism of lithium has recently been described. McCarthy et al. conducted a candidate gene association study for 16 variants 
in seven circadian clock genes and the response to lithium of 282 Caucasian patients with BD (55). They found that a variant in 
the promoter of NR1D1 (rs2071427) and a variant in cryptochrome-1 (CRY1; rs8192440) were nominally associated with the 
response to lithium (55). Also, GSK3β and NR1D1 genotypes considered together predicted the response to lithium robustly and 
additively; the response was proportional to the number of response-associated alleles (55).  
 
Glucocorticoid receptors are regulators of the circadian rhythm. A polymorphism of the glucocorticoid receptor gene 
(NR3C1) on chromosome 5q31-32 is associated with lithium responder status (56). Although the mechanism of action of lithium 
is not understood, it clearly interferes with the expression of circadian genes and this is involved in its mood stabilizing effect 
(53). These first results from pharmacogenetic studies with the circadian system are promising but still preliminary and further 
replications are required. 
 
5.1.2.3. The neurotransmitter system: serotonin, dopamine and GABA pathways 
Serretti et al. explored the dopamine, GABA and serotonin pathways and did not find any association between the 
efficacy of lithium and polymorphisms at the genes of any of the following: the D2 receptor (57), the D3 receptor (58), the D4 
receptor (57), the γ-aminobutyric acid (GABA) type A receptor α-1 subunit (57), and the 5-HT2A, 2C and 1A receptors (59). The 
same authors found an association between a functional polymorphism in the upstream regulatory region of the serotonin 
transporter gene (5-HTTLPR) and the prophylactic efficacy of lithium: 5-HTTLPR s/s variants were associated with a worse 
response to lithium than either l/s and l/l variants (60). These 5-HTTLPR s/s and l/s variants showed a significant epistatic 
interaction with the Val/Val genotype of brain-derived neurotrophic factor (BDNF) and response to lithium prophylaxis in a 
sample of 107 BD patients (61). In the study by Michelon et al., the 5-HTTLPR gene and BDNF gene variants were not 
predictive factors for the response to lithium prophylaxis (40). Manchia et al. investigated several polymorphisms of genes of the 
neurotransmitter system, including the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes, for association with response 
to lithium prophylaxis in a sample of 155 Sardinian BD probands (62). No association was found between the polymorphisms of 
these genes and the response to lithium treatment (62). A recent association study involving DRD1 showed an association 
between allele G at −48 A/G and a worse response to lithium (63). An additive association analysis of 5-HT2A and 5-HT2C 
serotonin receptor gene polymorphisms and the response of BD patients to lithium prophylaxis found no association (64). To 
summarize, four studies have reported associations between genotypes carrying the 5-HTTLPR s allele and a worse response to 
lithium (60,61,65,66). An association and linkage study confirmed the absence of association between the response to lithium and 
GABRA3, GABRA5 and GABRB3 subunits of the GABAA receptor (67). 
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Enzymes involved in the synthesis/catabolism of amines, including neurotransmitters, may be of relevance. Serretti et 
al. did not find any association between the prophylactic efficacy of lithium in mood disorders and the following variants of 
enzymes in the corresponding pathways: catechol-O-methyltransferase (COMT) G158A, monoamine oxidase A (MAO-A) 30-bp 
repeat, and G-protein beta 3-subunit (Gβ3) C825T (68). A further association and linkage study found no association between 
MAO-A and the response to lithium (69). The prophylactic efficacy of lithium may depend in part on variants of the tryptophan 
hydroxylase (TPH) gene, which is a serotonin-related gene. Subjects with the TPH A/A variant showed a trend toward a worse 
response to lithium than subjects with either TPH A/C or TPH C/C variants (70). An association study focused on the gene 
encoding tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis: it revealed no association in 54 
patients with the long-term response to lithium monotherapy (71). 
 
To conclude, the serotonin-related genes of the neurotransmitter system, and in particular the serotonin transporter 
gene, show the strongest evidence of interactions with the response to lithium prophylaxis. 
 
5.1.2.4. The BDNF/TrkB signaling pathway 
 BDNF-related genes have been implicated in the pathogenesis of BD and in the mechanism of action of lithium. 
Rybakowski et al. showed extreme differences in response to lithium prophylaxis between subjects according to their BDNF 
polymorphisms (61). Subsequent studies tended to validate this result and the Val/Met BDNF genotype at the Val66Met 
functional polymorphism showed a positive association with better response to lithium in a sample of 88 BD patients (72). The 
same authors provided a supplementary study investigating the association in the BDNF gene and polymorphisms in the gene 
encoding the neurotrophic tyrosine kinase receptor type 2 (NTRK2) (73). Among the four BDNF polymorphisms tested, two 
(C/G (rs988748) and G/A (rs6265)) showed an association with the response to lithium prophylaxis (73). No association was 
found between the response to lithium and either the interaction of BDNF and NTRK2 genes or polymorphism of the NTRK2 
gene alone (73). The Michelon et al and Masui et al studies did not find such results for BNDF (40,74).  
 
Lithium inhibits glutamatergic transmission via NMDA receptors, and the src-family tyrosine kinases (FYN) belong to 
the protein kinase family that phosphorylates NMDA receptor subunits, participating in the BDNF/TrkB signal transduction 
pathway. A marginal association between FYN polymorphisms and a worse response to lithium in 101 BD patients has been 
reported (75). The same authors investigated the association between three polymorphisms in the NMDA receptor 2B subunit 
(GRIN2B) gene and the response to lithium but did not find a significant association (76). 
 
These various findings suggest that the BDNF/TrkB signal transduction pathway may play a key role in the response to 
lithium prophylaxis. 
 
5.1.2.5. Other signaling pathways 
Lithium may affect the cyclic adenosine monophosphate (cAMP) pathway of signal transduction. The first relevant 
genetic study of BD found significant associations with the CREB1, CREB2 and CREB3 genes of this pathway (77). In a BD 
sample of 180 lithium responders and 69 non-responders, and 127 controls, the same authors found that two CREB1 
polymorphisms may be associated with BD and/or the response to lithium (77). In the same sample, there was no association 
between the propyl endopeptidase (PREP) gene l and the response to lithium (78).  
 
The endoplasmic reticulum (ER)-stress response, a potential pathophysiological mechanism of BD, involves various 
molecules including the X-box-binding protein 1 (XBP1). An association between the response to lithium and -116C/G 
polymorphism of XBP1 has been reported in Japanese BD patients (79). In the same BD Japanese population, this association 
was further confirmed, with -116C allele carriers showing a better response than -116G homozygotes to lithium (80). The same 
authors found a significant association between the breakpoint cluster region (BCR) gene and the response to lithium, observing 
that the allele frequency of the Asn796Ser single-nucleotide polymorphism was significantly higher in non-responders than in 
responders (81). 
The protein kinase C (PKC) pathway is an important mediator of several intracellular responses to neurotransmitter 
signaling. It has therefore been the subject of investigation, but a recent study failed to show any positive association between the 
response to lithium and PDLIM5 (PDZ and LIM domain 5), an adaptor protein that selectively binds the isozyme PKC (epsilon) 
to N-type Ca (2+) channels in neurons (82). Silberberg et al. investigated the calcium channel gamma-2 subunit (CACNG2, 
Stargazin) gene on 22q13.1 and found that three single nucleotide polymorphisms (rs2284017, rs2284018, rs5750285) were 
significantly associated with the response to lithium (83). 
 
These preliminary results need to be replicated before any conclusions can be drawn. Polymorphisms of the genes for 
activating enhancer-binding protein 2 beta 3 (AP2-B), the myristoylated alanine-rich C-kinase substrate (MARKS) and the beta-
adrenergic receptor kinase 2 (GRK3, BARK2) have been found not be to associated with the response to lithium (40,84). 
Rybakowski et al., who had previously reported an association between BD and a functional polymorphism of matrix 
metalloproteinase-9 (MMP-9) gene, tested for its involvement in the response to lithium and were unable to find any such 
association (85). 
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Recently, Rybakowski et al. aimed to replicate some of these earlier findings and tested the association of 14 gene 
polymorphisms with the quality of the response to lithium prophylaxis (86). The authors confirmed an association between the 
response to lithium and the polymorphisms of 5HTTLPR, DRD1, COMT, BDNF and FYN genes, but not those of 5HT2A, 
5HT2C, DRD2, DRD3, DRD4, GSK-3, NTRK2, GRIN2B and MMP-9. A list of these pharmacogenetic studies is provided in 
Table 1. 
 
5.1.3. Genome Wide Association Studies (GWAS) on the response to lithium  
An international consortium on lithium genetics (ConLiGen, www.conligen.org) is currently driving an international 
effort to elucidate the genetic underpinnings of the response of BD patient to lithium. The consortium aims to establish the largest 
ever sample of cases of BD characterized for their response to lithium treatment suitable for genome-wide studies (87). In 
particular, there is a particular effort to develop stringent definitions for the response phenotypes. This consortium has not yet 
published or made available any results, but the scientific community is awaiting the findings with high hopes.  
 
An early report described a sample of 359 BD patients characterized for the response to lithium and who were 
participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) cohort (88). The associations 
identified did not reach genome-wide significance, but the findings for two regions, on chromosome 10p15 (rs10795189) and 
chromosome 4q32 including a gene coding for the glutamate/alpha-amino-3-hydroxy-5-methyl-4-isoxazolpropionate (AMPA) 
receptor GRIA2, indicate that they deserve further examination (88). Squassina et al. performed a GWAS in a sample of 204 
Sardinian patients with BD characterized for response to lithium and found an association, supported by quantitative trait 
analysis, for a single nucleotide polymorphism (SNP) in intron 1 of the amiloride-sensitive cation channel 1 neuronal (ACCN1) 
gene (89). This cation channel has high affinity for sodium and is permeable to lithium and consequently is a putative genetic 
marker of lithium efficacy for patients with BD (89). However, this possibility needs to be confirmed. McCarthy et al. used a 
multi-level approach focusing on associations between circadian clock genes and BD compared to controls, and also considered 
the response to lithium (90). They reconciled discordant results from earlier GWAS and candidate gene studies by identifying 
recognized and previously unrecognized associations between clock genes and BD-spectrum illnesses (90). 
 
The results of these various approaches and the findings generated argue for continued GWAS of the response to 
lithium in BD patients. 
 
5.2. Pharmacogenomics of other mood stabilizers  
Almost all pharmacogenetic studies of MS have focused on the response to lithium but informative results are sparse. 
The situation for other MS is similarly, in addition to fewer reported studies. Thus, there is little evidence available for valproate 
and even less for lamotrigine. Lastly, we will review current evidence about atypical antipsychotics‘ pharmacogenetics. 
   
5.2.1.Valproate (VPA) 
The mechanism of action of valproate (VPA) is poorly understood and several hypotheses exist. The X-box-binding 
protein 1 (XBP1) is involved in the endoplasmic reticulum (ER)-stress response, and the 116C/G polymorphism in the promoter 
region of the corresponding gene is known to be associated with BD. An association between this polymorphism and the 
response to VPA has been reported (91): in a sample of 51 BD patients the G allele was associated with a better response to VPA 
than the C allele (91). The transcription activity of XBP1 was lower for the G allele than for the C allele. Thus VPA increases the 
endoplasmic reticulum (ER)-stress response, which is compromised by the G allele. Similarly, association between the -116C/G 
polymorphism and the clinical efficacy of lithium has been observed consistent with the notion that the XBP1 gene product is 
involved in the response to MS (91).  
 
The Val158Met polymorphism in the COMT gene is another candidate gene in the response to VPA and to lithium; its 
role was examined in a sample of 144 BDI patients and 157 controls (92). The study found that the Met/Met genotype was more 
frequent in non-responders than in responders to MS (either lithium, VPA or carbamazepine), whereas no differences were 
detected between BD patients and controls. Unfortunately, the sample was pooled for types of MS and therefore the study is 
uninformative about the role of COMT Val66Met in the response to individual mood stabilizers (92). Further studies with a larger 
numbers of subjects are required to elucidate the role of COMT gene polymorphism in the therapeutic response of BD patients to 
mood stabilizer. 
 
5.2.2. Lamotrigine (LTG) 
A pharmacogenetic study based on the response to LTG has been performed in 85 LTG-treated BD I depression 
patients. Polymorphisms in the dopamine D2 receptor (DRD2), dopamine β-hydroxylase (DBH), glucocorticoid receptor 
(NR3C1), histamine H1 receptor (HRH1) and melanocortin 2 receptor (MCR2) genes were associated with the response to 
treatment (93). As far as we are aware, this is the only pharmacogenetic study addressing LTG to be reported, no other results of 
studies of this type, relevant to conventional MS, have been published. Several pathways seem to be involved in the response to 
LTG, and might be, at least in part, shared by lithium and other conventional MS. 
 
5.2.3. Atypical antipsychotics (AAP) 
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Antipsychotic medication is widely used, being prescribed to between 72% and 92% of patients with mania (94). 
Despite this extensive use of AAP in the treatment of BD, pharmacogenetic studies are again lacking and very few studies have 
investigated the genetic underpinnings of the therapeutic response. Furthermore, these few studies only included patients during 
acute phases of BD.  
 
Perlis et al. investigated common genetic variations for association with clinical improvement in a cohort of 88 BD I 
depression patients following treatment with an olanzapine/fluoxetine combination (OFC) (93). They found significant 
associations between polymorphisms in the dopamine D (3) receptor (DRD3) and HRH1 genes, and response to OFC (93). 
Subsequently, in the same population, they found an association between the response to OFC and polymorphisms in the 
norepinephrine transporter (SLC6A2) gene, the melanocortin 3 receptor (MC3R) gene and the tryptophan hydroxylase 2 (TPH2) 
gene (95). 
 
 Furthermore, Dávila et al. investigated the role of the COMT Val158Met polymorphism in the plasma concentration 
of catecholamine metabolites and clinical features in 42 BD I patients (96). Authors found no significant association with the 
response to olanzapine treatment or with any of the markers tested, including the plasma concentrations of metabolites of 
dopamine (homovanillic acid; HVA) and of noradrenaline (3-methoxy-4-hydroxyphenylglycol; MHPG). Nevertheless, in the 
homozygous Val-Val group, a non-significant aggregation of BD patients presenting with psychosis was found; and clinical 
improvement significantly correlated with the plasma concentration of MHPG prior to treatment. The preliminary findings of 
these two studies are of interest and further work on these issues would be fruitful. 
 
Table 2 presents published pharmacogenetic studies of the response to various mood-stabilizing medications. In view 
of the widespread and increasing prescription of antipsychotics to patients with BD further research efforts in pharmacogenetics 
to identify possible genetic predictors of response would be extremely valuable. 
 
6. SUMMARY AND PERSPECTIVES 
 
To prescribe MS appropriately to patients, predictors of the response are required. Various genetic markers are 
considered to be promising candidates. In this review, we present diverse findings that are promising, and further investigation is 
warranted for confirmation. It seems very likely that the response to MS has a complex genetic heritability. Candidate genes 
associated with BD display relatively low odds ratios (OR) and minor allele frequencies (MAF), and therefore it is unlikely that 
the response to MS is determined by common variants with large effect-sizes.  
 
Furthermore, specific clinical features, family history, comorbidities and clinical course are factors that may be closely 
linked to the MS response phenotype and thus may help to understand its complex genetic heritability. For example, A.  Bremer 
et al observed that polymorphisms in NTRK2 and INPP1 genes were associated with the response to lithium, and also with both 
suicidal ideation and post-traumatic stress disorder; this indicates that the response to lithium  in BD and clinical co-morbidities 
share, at least partly, genetic determinants (84).  
 
This review leads us to suggest several putative goals for pharmacogenomics research in BD: genetic research in mood 
disorders can be reasonably expected to contribute in the following areas associated with treatment effects: 1) prediction of 
treatment response in individual patients; 2) prediction of side effects; 3) development of personalized therapies; 4) identification 
of homogeneous clinical subgroups of BD for genetic studies; 5) identification of causative determinants of BD; 6) identification 
of new treatment pathways; 7) development of gene therapy for BD; and 8) findings that are relevant to other psychiatric 
diseases. Some of the goals that we believe are important for pharmacogenomics research in BD are summarized in Figure 1. 
 
These approaches are however subject to several limitations, and as a consequence of some of them, the interpretation 
of pharmacogenetic results can be difficult (summarized in Table 1 as relevant to the efficacy of lithium prophylaxis). First, 
diagnostic heterogeneity in patient groups prevents rigorous comparison between studies. The definitions of the response to MS 
(see table 1 and 2) are not consensual and differ between studies. Clearly, valid and consensual definitions of probands and clear 
criteria for the definition of the response to MS are needed for results to be reliable and comparable.  
 
Also, most of the candidate genes studied were chosen for their possible association with mood disorders, rather than 
for their putative role in the mechanism of action of lithium or other MS. Future studies on biological and genetic factors 
associated with lithium response will have to consider potential confounders such as compliance and co-administration of 
circadian rhythm therapy, other psychotropic drugs or psychotherapy. Finally, sample sizes in these studies are often small; 
prospective studies with larger samples are required to study the response to MS.  
 
7. CONCLUSION  
 
To date, the results from pharmacogenomics studies are not sufficiently abundant, informative or conclusive to have 
significantly changed daily practice in the management of BD. The clinical assessment of a subject with the identification of 
specific individual phenotypic and pharmacogenetics data may nevertheless become a powerful approach for the development of 
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personalized therapies. Further pharmacogenomics studies are needed to validate reliable and reproducible predictors of 
individual responses to MS and MS safety. Advances made in pharmacogenomics may help the clinician select appropriate 
effective treatment and monitoring, leading to more personalized treatment algorithms that are currently lacking for BD.  
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 Table 1. Pharmacogenetic studies on the response to lithium in bipolar disorder 
Gene Sample 
Association 
(Yes/No) 
Study design Definition of response Reference 
The inositol pathway 
INPP1 a) 23 BD + 20 
controls 
b) 54 BD I + 50 
controls  
a) Yes 
b) No 
Retrospective a) R: demonstrated ―complete lithium response‖ 
b) R: demonstrated ―long and complete remission‖ on 
lithium alone 
(39) 
 134 BD I  No Retrospective R ‗‗ Good responders‘‘: no recurrence of impairing 
symptoms, or recurrence of mild symptoms, promptly 
controlled by adjusting the lithium dose or with short 
courses of benzodiazepines but no other medication. 
PR : lithium level ≥0.6 mEq/l with improvement of the 
recurrence pattern in spite of being mildly depressed or 
hypomanic while on monotherapy. 
(40) 
 184 BD  
(92R, 92NR) 
Yes 
(in BD with 
post-
traumatic 
stress 
disorder) 
Retrospective R: rated retrospectively from standardized interviews and 
medical records 
(84) 
IMPA2 237 parents-
offspring trios 
and 174 cases 
ascertained for  
their response 
to lithium and 
170 controls 
Yes Retrospective ‗‗ Good responders‘‘: patients recruited for genetic 
association studies had clearly shown a good response to 
lithium 
 
‗‗Poor responders‘‘: some of these patients experienced no 
benefit at all 
(41) 
 a)44 
Norwegian 
lithium-treated 
patients with 
BD  
b) 75 nuclear 
families from a 
Palestinian 
Arab trio 
sample with 
BD  
a) No 
b) Yes 
Retrospective a) classified retrospectively according to the clinical 
history, with comparison of the frequency, duration and 
severity of episodes before and after treatment 
b) demonstrated ―long and complete remission‖ on lithium 
alone 
(42) 
 184 BD  
(92R, 92NR) 
No Retrospective R: rated retrospectively from standardized interviews and 
medical records 
(84) 
IMPA1 
 
184 BD  
(92R, 92NR) 
No Retrospective R: rated retrospectively from standardized interviews and 
medical records 
(84) 
 a)44 
Norwegian 
lithium-treated 
patients with 
BD  
b) 75 nuclear 
families from a 
Palestinian 
Arab trio 
sample with 
BD  
a) No 
b) No 
Retrospective a) classified retrospectively according to the clinical 
history, with comparison of the frequency, duration and 
severity of episodes before and after treatment 
b) demonstrated ―long and complete remission‖ on lithium 
alone 
(42) 
 21 BD patients  
(7R, 7NR, 
7UN) 
No Retrospective classified retrospectively according to the clinical history (43) 
DGKH 91 BD lithium 
responders 
(24FR, 
67PR+NR) 
No Retrospective Response to lithium: assessed using the scale of Grof et al. 
(24).  
(46) 
 199 BD lithium 
responders 
(57FR, 
142PR+NR) 
No Retrospective Response to lithium: assessed using the scale of Grof et al. 
(24).  
(45) 
PLCG1 
 
a) 136 BD 
lithium 
responders 
163 controls 
b) 32 families 
ascertained 
through 
lithium-
responsive BD 
probands 
a) Yes 
b) Yes 
(when 
unilineal 
families 
were 
considered) 
Prospective Response to lithium was evaluated prospectively with an 
average follow-up of 14.4 ± 6.8 years. 
(47) 
 133 BD lithium 
responders 
No Prospective Patients were stabilized on lithium monotherapy for an 
average of 14.4 ± 9 years 
(48) 
 16 
99 controls 
 
 61 BD  
(29R, 16NR, 
16PR/UN) 
 
No 
(only a 
PLCG1-8 
repeat was 
more 
frequent 
among R) 
Retrospective Retrospectively subclassified as lithium R, NR, or PR/UN 
according to the clinical history, with comparison of the 
frequency, duration and severity of episodes before and 
after lithium therapy. 
(49) 
The circadian signaling system 
NR1D1 199 BD lithium 
responders 
(57FR, 
142PR+NR) 
No Retrospective Response to lithium: assessed using the scale of Grof et al. 
(24).  
(45) 
 170 BD Yes Prospective R: minor or modest improvement in frequency of episodes 
or admissions. 
(54) 
 282 BD (148R, 
134NR) 
Yes Retrospective R: if there was a 50% reduction in the frequency and/or 
severity of symptoms on Li.  
NR: if less than 50% symptom reduction. 
(55) 
NR3C1 115 BD  
(30ER, 58PR, 
27NR) 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to pre-lithium period  
NR: < 50% reduction, no change or worsening in the 
episode index, defined as number of episodes per year 
compared to the pre-lithium period. 
(56) 
GSK3β 
 
88 BD I lithium 
responders 
Yes 
 
Prospective Efficacy of lithium was evaluated by calculating the 
difference between the ―pre-lithium treatment recurrence 
index‖ and the ―on-lithium treatment recurrence index‖. 
(51) 
 134 BD I  No Retrospective R ‗‗ Good responders‘‘: no recurrence of impairing 
symptoms, or recurrence of mild symptoms, promptly 
controlled by adjusting the lithium dose or with short 
courses of benzodiazepines but no other medication. 
PR: lithium level ≥0.6 mEq/l with improvement of the 
recurrence pattern in spite of being mildly depressed or 
hypomanic while on monotherapy. 
(40) 
 89 BD  
(23 ER, 47 PR, 
19 NR) 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to pre-lithium period  
NR: < 50% reduction, no change or worsening in the 
episode index, defined as number of episodes per year 
compared to the pre-lithium period. 
(52) 
 184 BD  
(92R, 92NR) 
No Retrospective R: rated retrospectively from standardized interviews and 
medical records 
(84) 
 282 BR (148R, 
134NR) 
No: alone 
Yes: when 
GSK3β and 
NR1D1 
genotypes 
were 
considered 
together 
Retrospective R: if there was a 50% reduction in the frequency and/or 
severity of symptoms on Li.  
NR: if less than 50% reduction of symptoms. 
(55) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to pre-lithium period  
NR: < 50% reduction, no change or worsening in the 
episode index 
(86) 
CRY1 282 BR (148R, 
134NR) 
Yes Retrospective R: if there was a 50% reduction in the frequency and/or 
severity of symptoms on Li.  
NR: if less than 50% reduction of the symptoms. 
(55) 
The neurotransmitter system: serotonin, dopamine and GABA pathways 
DRD1 155 BD  
(43R, 112PR + 
NR) 
No Retrospective The response to lithium was assessed using the scale 
developed by Grof et al. (24) 
(45) 
 92 BD  
(24ER, 48PR, 
20NR) 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening in the 
episode index, defined as number of episodes per year 
compared to the pre-lithium period. 
(63) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to pre-lithium period  
NR: < 50% reduction, no change or worsening in the 
episode index 
(86) 
DRD2 125 patients  
(100BD; 
25MD) 
No Prospective Efficacy evaluated by the difference between a pre-
treatment index and an ongoing treatment index 
(57) 
 155 BD  
(43R, 112PR + 
No Retrospective The response to lithium was assessed using the scale 
developed by Grof et al. (24) 
(45) 
 17 
NR) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
DRD3 155 BD  
(43R, 112PR + 
NR) 
No Retrospective The response to lithium was assessed using the scale 
developed by Grof et al. (24) 
(45) 
 55 patients  
(43BD; 12MD) 
No Prospective Efficacy evaluated as the difference between a pre-
treatment index and an ongoing treatment index 
(58) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
DRD4 125 patients  
(100BD; 
25MD) 
No Prospective Efficacy evaluated as the difference between a pre-
treatment index and an ongoing treatment index 
(57) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
DAT1 155 BD  
(43R, 112PR + 
NR) 
No Retrospective The response to lithium response was assessed using the 
scale developed by Grof et al. (24) 
(45) 
GABRA1 125 patients  
(100BD; 
25MD) 
No Prospective Efficacy evaluated as the difference between a pre-
treatment index and an ongoing treatment index 
(57) 
GABRA3 a) 138 BDI 
lithium 
responders and 
108 controls 
b) 24 families 
ascertained 
through 
lithium-
responsive BD 
probands 
a) No 
b) No 
Prospective Patients were stabilized on lithium monotherapy  (67) 
GABRA5 a) 138 BDI 
lithium 
responders and 
108 controls 
b) 24 families 
ascertained 
through 
lithium-
responsive BD 
probands 
a) No 
b) No 
Prospective Patients were stabilized on lithium monotherapy  (67) 
GABRB3 a) 138 BDI 
lithium 
responders and 
108 controls 
b) 24 families 
ascertained 
through 
lithium-
responsive BD 
probands 
a) No 
b) No 
Prospective Patients were stabilized on lithium monotherapy  (67) 
5-HT1A 124 patients  
(102BD; 
22MD) 
No Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(59) 
5-HT2A 
 
124 patients  
(102BD; 
22MD) 
No Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(59) 
 155 BD  
(43R, 112PR + 
NR) 
No Retrospective The response to lithium response was assessed using the 
scale developed by Grof et al. (24) 
(45) 
 92 BD  
(24ER, 48PR, 
20NR) 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index, defined as number of episodes per year 
compared to the pre-lithium period. 
(64) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
(86) 
 18 
episode index 
5-HT2C 124 patients  
(102BD; 
22MD) 
No Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(59) 
 92 BD  
(24ER, 48PR, 
20NR) 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening in the 
episode index, defined as number of episodes per year 
compared to the pre-lithium period. 
(64) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
5-
HTTLPR 
 
201 patients  
(167BD, 
34MD) 
Yes 
(s/s and 
worse 
response) 
Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(60) 
 83 BD  
(36R, 47NR) 
Yes 
(l/s and 
better 
response) 
Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(65) 
 67 BD  
(18ER, 35PR, 
14NR) 
Yes 
(s/s and s 
and worse 
response) 
Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index, defined as number of episodes per year 
compared to the pre-lithium period. 
(66) 
 121 BD  
(31ER, 54PR, 
26NR) 
Interaction 
between 
BDNF and 
5HTTLPR 
polymorphis
m and the 
response to 
lithium  
Retrospective ER: no affective episodes 
PR: 50% reduction in the number of episodes per year 
compared to the pre-lithium period 
(61) 
 134 BD I  No Retrospective R ‗‗ Good responders‘‘: no recurrence of impairing 
symptoms, or recurrence of mild symptoms, promptly 
controlled by adjusting the lithium dose or with short 
courses of benzodiazepines but no other medication. 
PR: lithium level ≥0.6 mEq/l with improvement of the 
recurrence pattern in spite of being mildly depressed or 
hypomanic while on monotherapy. 
(40) 
 155 BD  
(43R, 112PR + 
NR) 
No Retrospective The response to lithium was assessed using the scale 
developed by Grof et al. (24) 
(45) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
COMT 201 patients 
(160 BD + 
41MD 
characterized 
for lithium 
response) 
No Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(68) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year compared to pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
MAO-A 201 patients 
(160 BD + 
41MD 
characterized 
for lithium 
response) 
No Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(68) 
 a) 138 BD and 
108  controls 
b) 25 families 
ascertained 
through 
lithium-
responsive BD 
probands 
a) No 
b) No 
Prospective The response to lithium was evaluated prospectively with 
an average follow-up of 14.4 ± 6.8 years. 
(69) 
Gβ3 201 patients 
(160 BD + 
No Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
(68) 
 19 
41MD 
characterized 
for lithium 
response) 
recurrence index 
TPH 108 patients  
(90BD + 18MD 
characterized 
for lithium 
response) 
Yes  Prospective Efficacy evaluated as the difference between a pre-lithium 
treatment recurrence index and an on-lithium treatment 
recurrence index 
(70) 
TH 54 BD lithium 
responders (48 
BD and 6 RU) 
94 controls 
No Retrospective ER: patients judged to have a high risk of recurrence on the 
basis of the number and frequency of episodes before 
lithium therapy. Maintained on lithium monotherapy for ≥3 
years, at plasma levels ≥0.6 mEq/l, with no further 
episodes of the illness while on adequate treatment. No 
additional biological or pharmacological interventions 
allowed. 
(71) 
The BDNF/TrkB signaling pathway  
BDNF 
 
88 BD 
characterized 
for response to 
lithium 
Yes  Retrospective ER: had no affective episodes on lithium;  
PR: showed 50% reduction in the episode index (number 
of episodes per year relative to that during the pre-lithium 
period);  
NR : showed <50% reduction, no change, or worsening of 
the episode index. 
(45) 
 108 BD  
(25ER, 55PR, 
28NR) 
Yes Retrospective ER: had no affective episodes on lithium;  
PR: showed 50% reduction in the episode index (number 
of episodes per year relative to that during the pre-lithium 
period);  
NR: showed <50% reduction, no change, or worsening of 
the episode index. 
(73) 
 134 BD I  No Retrospective R ‗‗ Good responders‘‘: no recurrence of impairing 
symptoms, or recurrence of mild symptoms, promptly 
controlled by adjusting the lithium dose or with short 
courses of benzodiazepines but no other medication. 
PR: lithium level ≥0.6 mEq/l with improvement of the 
recurrence pattern in spite of being mildly depressed or 
hypomanic while on monotherapy. 
(40) 
 184 BD  
(92R, 92NR) 
No Retrospective The response to lithium was rated retrospectively from 
standardized interviews and medical records 
(84) 
 121 BD  
(31ER, 54PR, 
26NR) 
Yes Retrospective ER: had no affective episodes on lithium;  
PR: showed 50% reduction in the episode index (number 
of episodes per year relative to that during the pre-lithium 
period);  
NR: showed <50% reduction, no change, or worsening of 
the episode index. 
(61) 
 161 BD No Retrospective R: Less frequent and/or severe relapses, including no 
relapse, by comparison with the period before the initiation 
of lithium treatment 
(74) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, defined as number 
of episodes per year, since the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
NTRK2 108 BD  
(25ER, 55PR, 
28NR) 
No Retrospective ER: had no affective episodes on lithium;  
PR: showed 50% reduction in the episode index (relative to 
that during the pre-lithium period);  
NR: showed <50% reduction, no change, or worsening of 
the episode index. 
(73) 
 184 BD  
(92R, 92NR) 
Yes 
(in BD with 
suicidal 
ideation) 
Retrospective The response to lithium was rated retrospectively from a 
standardized interviews and medical records 
(84) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, from that during 
the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
FYN 101 BD  
(24ER, 51PR, 
26NR) 
Yes 
 
Retrospective ER: had no affective episodes on lithium;  
PR: showed 50% reduction in the episode index (from that 
during the pre-lithium period);  
NR: showed <50% reduction, no change, or worsening of 
the episode index. 
(75) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
Yes Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, from that during 
the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
GRIN2B 105 BD  
(24ER, 53PR, 
28NR) 
No Retrospective ER: had no affective episodes on lithium;  
PR: showed 50% reduction in the episode index (from that 
during the pre-lithium period);  
(76) 
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NR: showed <50% reduction, no change, or worsening of 
the episode index. 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, from that during 
the pre-lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
Other signaling pathways 
CREB1 249 BD (180R, 
69NR)  
and 127 
controls 
Yes Prospective ER: Each patient had to fulfill several criteria: A) 
Diagnosis of primary episodic bipolar disorder based on 
the SADS-L (lifetime version) interview and Research 
Diagnostic Criteria (RDC); B) High recurrence risk; and C) 
Unequivocal response to lithium  
NR: had to experience at least two recurrences during 
lithium treatment with confirmed therapeutic levels of 
lithium 
(77) 
CREB2 
CREB3 
249 BD (180R, 
69NR)  
and 127 
controls 
No Prospective ER: Each patient had to fulfill the following criteria: A) 
Diagnosis of primary episodic bipolar disorder based on 
the SADS-L (lifetime version) interview and Research 
Diagnostic Criteria (RDC) ; B) High recurrence risk ; and 
C) Unequivocal response to lithium 
NR: had to experience at least two recurrences during 
lithium treatment with confirmed therapeutic levels of 
lithium 
(77) 
PREP 249 BD (180R, 
69NR)  
and 127 
controls 
No Prospective ER: Each patient had to fulfill the following criteria: A) 
Diagnosis of primary episodic bipolar disorder based on 
the SADS-L (lifetime version) interview and Research 
Diagnostic Criteria (RDC) ; B) High recurrence risk ; and 
C) Unequivocal response to lithium  
NR: had to experience at least two recurrences during 
lithium treatment with confirmed therapeutic levels of 
lithium 
(78) 
XBP1 66 BD 
 
Yes Retrospective R: Less frequent and/or severe relapse, including no 
relapse, than during the period before the initiation of 
lithium treatment 
(80) 
BCR 161 BD (43R, 
118NR) 
Yes Retrospective R: full response without any affective episode during 
lithium treatment (=ER). 
(81) 
AP2-B 134 BD I  No Retrospective R ‗‗ Good responders‘‘: no recurrence of impairing 
symptoms, or recurrence of mild symptoms, promptly 
controlled by adjusting the lithium dose or with short 
courses of benzodiazepines but no other medication. 
PR: lithium level ≥0.6 mEq/l with improvement of the 
recurrence pattern in spite of being mildly depressed or 
hypomanic while on monotherapy. 
(40) 
PDLIM5 155 BD  
(43R, 112PR + 
NR) 
No Retrospective The response to lithium was assessed using the scale 
developed by Grof et al. (24) 
(82) 
CACNG2 a) 213 BD I 
b) 170 BD 
a) Yes 
b) Yes 
Retrospective NR: no improvement or worsening of illness  
PR: minor or modest improvement in frequency of 
episodes or admissions; significant morbidity 
R: partial good response (marked improvement but not 
episode-free)  
FR: good response (complete remission). 
(83) 
MMP-9 109 BD (26ER, 
55PR, 28NR) 
No Prospective ER: no affective episodes during lithium treatment;  
PR: 50% or more reduction in the episode index;  
NR: less than 50% reduction, no change or worsening of 
the episode index. 
(85) 
 101 BD 
(24ER, 51PR, 
26NR) 
 
No Retrospective ER: no affective episodes on lithium 
PR: 50% reduction in the episode index, since the pre-
lithium period  
NR: < 50% reduction, no change or worsening of the 
episode index 
(86) 
BD: bipolar disorder; MD: major depression; RU: recurrent unipolar; ER: excellent responders; FR: full responders; R: 
responders; PR: partial or poor responders; NR: non responders; UN: unclassified. 5-HT1A: 5-hydroxytryptamine receptor 1A; 5-
HT2A: 5-hydroxytryptamine receptor 2A; 5-HT2C: 5- hydroxytryptamine receptor 2C; 5-HTT: solute-carrier family 6 member 4 
(serotonin transporter); 5-HTTLPR: serotonin-transporter-linked promoter region; AP2-B: activating enhancer- binding protein 2 
beta 3; BCR: breakpoint cluster region; BDNF: brain-derived neurotrophic factor; CREB1: cAMP-responsive element-binding 
protein 1; COMT: catechol-O-methyl transferase; CREB2: cAMP-responsive element-binding protein 2; CREB3: cAMP-
responsive element-binding protein 3; CRY1: cryptochrome-1 ; DAT1: dopamine transporter 1; DGKH: diacylglycerol kinase, 
eta; DRD1: dopamine receptor D1; DRD2: dopamine receptor D2; DRD3: dopamine receptor D3; DRD4: dopamine receptor D4; 
GABRA1: gamma-aminobutyric acid A receptor, alfa 1; GABRA3: gamma-aminobutyric acid A receptor, alfa 3; GABRA5: 
gamma-aminobutyric acid A receptor, alfa 5; GABRB3: gamma-aminobutyric acid A receptor, beta 3; Gβ3: G protein beta 3; 
GRIN2B: NMDA receptor 2B subunit ; GRK3: beta-adrenergic receptor kinase 2 (BARK2); GSK3B: glycogen synthase kinase 3 
beta; FYN: Src-family tyrosine kinases; IMPA1: inositol(myo)-1(or 4)-monophosphatase 1; IMPA2: inositol(myo)-1(or 4)-
monophosphatase 2; INPP1: inositol polyphosphate-1-phosphatase; MAO-A: monoamine oxidase A; MARKS: myristoylated 
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alanine-rich C-kinase substrate; group D, member 1; MMP-9: matrix metalloproteinase-9; NR1D1: nuclear receptor subfamily 1, 
group D, member 1; NR3C1: nuclear-receptor subfamily 3, group C, member 1 ; NTRK2: neurotrophic tyrosine kinase, receptor, 
type 2; PDLIM5: PDZ and LIM domain 5; PLCG1: phospholipase C, gamma 1; PREP: propyl endopeptidase; TH: tyrosine 
hydroxylase; TPH: tryptophan hydroxylase; XBP1: X-box-binding protein 1. 
 
 
Table 2. Pharmacogenetic studies of the response of bipolar disorder patients to non-lithium mood stabilizers 
Gene Sample 
Association 
(Yes/No) 
Study design Definition of response References 
Valproate (VPA) 
XBPI 
51 BD patients 
 
Yes 
Retrospective 
Less frequent and/or severe relapse, including no relapse, than 
during the period before the initiation of valproate treatment 
(91) 
Lamotrigine 
DRD2 
85 lamotrigine-
treated, BD I 
depression patients  
 
Yes 
Prospective 
Reduction in Montgomery-Asberg Depression Rating Scale 
(MADRS) total score between baseline and week 7. 
(93) 
DRD3 No 
DRD4 No 
DBH Yes 
HRH1 Yes 
ANKK1 No 
MCR2 Yes 
NR3C1 Yes 
Atypical antipsychotics 
DRD2 
88 
olanzapine/fluoxetine 
combination (OFC)-
treated BD I 
depression patients 
No 
Prospective 
Reduction in Montgomery-Asberg Depression Rating Scale 
(MADRS) total score between baseline and week 7. 
(93) 
DRD3 Yes 
DRD4 No 
DBH No 
HRH1 Yes 
ANKK1 No 
MCR2 No 
NR3C1 No 
SLC6A2 88 
olanzapine/fluoxetine 
combination (OFC)-
treated BD I 
depression patients 
Yes 
Prospective 
Reduction in Montgomery-Asberg Depression Rating Scale 
(MADRS) total score between baseline and week 7. 
(95) 
MCR3 Yes 
TPH2 Yes 
COMT 42 BD patients 
characterized for 
response to 
olanzapine 
No Prospective Clinical status evaluated before treatment, after 4 days of 
treatment and subsequently every week, with the Young scales 
for mania and the Andreasen scale for positive symptoms.  
(96) 
Common to Lithium, VPA and carbamazepine  
COMT 
144 BD patients 
characterized for 
response to mood 
stabilizers (Li, VPA, 
CBZ) 
and 157 controls. 
Yes Prospective 
Response defined as subjects exhibiting a decrease of at least 
50% in the YMRS score after 6 weeks of medication. 
(92) 
BD: bipolar disorder; R: responders; NR: non responders. ANKK1: ankyrin repeat and kinase domain containing 1; COMT: 
catechol-O-methyl transferase; DBH: dopamine beta-hydroxylase; DRD2: dopamine receptor D2; DRD3: dopamine receptor D3; 
DRD4: dopamine receptor D4; HRH1: histamine H1 receptor; MCR2: melanocortin 2 receptor; MCR3: melanocortin 3 receptor ; 
NR3C1: nuclear receptor subfamily 3, group C, member; SLC6A2: norepinephrine transporter ; TPH2: tryptophan hydroxylase 2 
; XBP1: X-box-binding protein 1. 
 
 
 
Figure 1. Goals of the pharmacogenomics research in bipolar disorder. 
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